Another systematic review searched for quantitative and qualitative evidence to explore ‘values, preferences and burden of treatment for the initiation of GLP‐1 receptor agonists and SGLT‐2 inhibitors in adults with Type 2 diabetes’ [9]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.